Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis

Published:2011-12 Issue:12 Volume:50 Page:793-807
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clinical Pharmacokinetics

Author:

Sutjandra Liviawati,Rodriguez Rachelle D.,Doshi Sameer,Ma Mark,Peterson Mark C.,Jang Graham R.,Chow Andrew T.,Pérez-Ruixo Juan José

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference47 articles.

1. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

2. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

3. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

4. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts

5. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects;Clinical and Translational Science;2024-08-29

2. Hypercalcemia in children induced by denosumab: a case report and an analysis of the FDA adverse event reporting system database;Expert Opinion on Drug Safety;2024-07-15

3. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations;PLOS Computational Biology;2024-04-24

4. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study;Journal of Bone and Mineral Research;2024-01-29

5. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males;Expert Opinion on Biological Therapy;2024-01-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3